Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

NEXT STORY
Algenex and Global DX Announce Positive Evaluation of Herdscreen® ASFV Antibody Test for African Swine Fever
PREV STORY
Burning Rock Schedules Second Quarter of 2020 Earnings Release on August 11, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NewLink Genetics Corporation Provides Operational Update and Reports Third Quarter 2016 Financial Results

AMES, Iowa, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

Strategic partnership enables physicians to conduct clinical research and offer new clinical therapies to their patients

CHICAGO, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ:MDRX) has partnered with Elligo Health Research ...

author_avatar
NASDAQ Market News

Great Basin Scientific Announces Filing of Registration Statement on Form S-1

SALT LAKE CITY, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), ...

author_avatar
NASDAQ Market News